GlassScriptPhysician profile
Andrew Mark Lopez
NPI 1730232562
$1,484.90
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.69 · 2020: $14.22 · 2021: $1,314 · 2022: $65.73 · 2023: $16.98 · 2024: $16.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $33.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $33.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $243.12 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $201.20 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $191.13 | 2021-2024 | Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $150.99 | 2021 | |
| Alkermes, INC. | $115.95 | 2021 | |
| Sunovion Pharmaceuticals INC. | $91.82 | 2021 | |
| Avanir Pharmaceuticals, INC. | $76.23 | 2021 | |
| Adlon Therapeutics L.P. | $68.87 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $57.82 | 2021 | |
| Tris Pharma INC | $55.81 | 2021 | |
| Lundbeck LLC | $49.03 | 2019-2021 | |
| Bausch Health US, LLC | $42.82 | 2021 | |
| Merck Sharp & Dohme LLC | $39.02 | 2021 | |
| Neos Therapeutics, LP | $27.80 | 2021 | |
| Eisai INC. | $26.69 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $17.85 | 2019 | |
| Allergan, INC. | $16.55 | 2019 | |
| Noven Therapeutics, LLC | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.